Tumor Biology

, Volume 35, Issue 11, pp 11153–11158 | Cite as

RETRACTED ARTICLE: Betulin inhibits lung carcinoma proliferation through activation of AMPK signaling

Research Article

Abstract

Betulin (lup-20(29)-ene-3β, 28-diol) is an abundant, naturally occurring triterpene. It is commonly isolated from the bark of birch trees and forms up to 30 % of the dry weight of the extractive. In the present study, we revealed its antiproliferative effects and mechanisms using two lung carcinoma cells (A549 and NCI-292). By 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) and bromodeoxyuridine (BrdU) incorporation assays, we found that betulin could efficiently inhibit cell growth and proliferation. Besides, several key genes of cell-cycle regulators were also affected by betulin treatment. At the molecular level, our results demonstrated that treatment with betulin was also associated with activation of AMP kinase and inhibition of mTOR/p70S6K/pS6 signaling in these cells. In agreement, inhibition of AMPK signaling largely reversed the antiproliferative roles of betulin. Taken together, these data provide evidence for a mechanism that may contribute to the antineoplastic effects of betulin and justify further work to explore its potential roles in lung cancer prevention and treatment.

Keywords

Betulin Lung carcinoma Proliferation AMPK signaling 

Notes

Conflict of interest

None.

References

  1. 1.
    Keith RL, Miller YE. Lung cancer chemoprevention: current status and future prospects. Nat Rev Clin Oncol. 2013;10:334–43.CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Berkovich L, Ron I, Earon G, Abu-Ghanem S, Rimmon A, Lev-Ari S. The role of medicinal herbs with anti-inflammatory properties in prevention and treatment of cancer. Harefuah. 2012;151(629-632):654.Google Scholar
  3. 3.
    McLeod HL. Cancer pharmacogenomics: early promise, but concerted effort needed. Science. 2013;339:1563–6.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Ali R, Mirza Z, Ashraf GM, Kamal MA, Ansari SA, Damanhouri GA, et al. New anticancer agents: recent developments in tumor therapy. Anticancer Res. 2012;32:2999–3005.PubMedGoogle Scholar
  5. 5.
    Dehelean CA, Feflea S, Molnar J, Zupko I, Soica C. Betulin as an antitumor agent tested in vitro on a431, hela and mcf7, and as an angiogenic inhibitor in vivo in the cam assay. Nat Prod Commun. 2012;7:981–5.PubMedGoogle Scholar
  6. 6.
    Li Y, He K, Huang Y, Zheng D, Gao C, Cui L, et al. Betulin induces mitochondrial cytochrome c release associated apoptosis in human cancer cells. Mol Carcinog. 2010;49:630–40.PubMedGoogle Scholar
  7. 7.
    Rzeski W, Stepulak A, Szymański M, Juszczak M, Grabarska A, Sifringer M, et al. Betulin elicits anti-cancer effects in tumour primary cultures and cell lines in vitro. Basic Clin Pharmacol Toxicol. 2009;105:425–32.CrossRefPubMedGoogle Scholar
  8. 8.
    Kommera H, Kaluđerović GN, Kalbitz J, Paschke R. Lupane triterpenoids-betulin and betulinic acid derivatives induce apoptosis in tumor cells. Invest New Drugs. 2011;29:266–72.CrossRefPubMedGoogle Scholar
  9. 9.
    Pyo JS, Roh SH, Kim DK, Lee JG, Lee YY, Hong SS, et al. Anti-cancer effect of Betulin on a human lung cancer cell line: a pharmacoproteomic approach using 2 D SDS PAGE coupled with nano-HPLC tandem mass spectrometry. Planta Med. 2009;75:127–31.CrossRefPubMedGoogle Scholar
  10. 10.
    Wang HM, Soica CM, Wenz G. A comparison investigation on the solubilization of betulin and betulinic acid in cyclodextrin derivatives. Nat Prod Commun. 2012;7:289–91.PubMedGoogle Scholar
  11. 11.
    Dehaen W, Mashentseva AA, Seitembetov TS. Allobetulin and its derivatives: synthesis and biological activity. Molecules. 2011;16:2443–66.CrossRefPubMedGoogle Scholar
  12. 12.
    Alakurtti S, Makela T, Koskimies S, Yli-Kauhaluoma J. Pharmacological properties of the ubiquitous natural product betulin. Eur J Pharm Sci. 2006;29:1–13.CrossRefPubMedGoogle Scholar
  13. 13.
    Krycer JR, Phan L, Brown AJ. A key regulator of cholesterol homoeostasis, srebp-2, can be targeted in prostate cancer cells with natural products. Biochem J. 2012;446:191–201.CrossRefPubMedGoogle Scholar
  14. 14.
    Shackelford DB, Shaw RJ. The lkb1-ampk pathway: metabolism and growth control in tumour suppression. Nat Rev Cancer. 2009;9:563–75.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Linehan WM, Srinivasan R, Schmidt LS. The genetic basis of kidney cancer: a metabolic disease. Nat Rev Urol. 2010;7:277–85.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Buzzai M, Jones RG, Amaravadi RK, Lum JJ, DeBerardinis RJ, Zhao F, et al. Systemic treatment with the antidiabetic drug metformin selectively impairs p53-deficient tumor cell growth. Cancer Res. 2007;67:6745–52.CrossRefPubMedGoogle Scholar
  17. 17.
    Huang X, Wullschleger S, Shpiro N, McGuire VA, Sakamoto K, Woods YL, et al. Important role of the lkb1-ampk pathway in suppressing tumorigenesis in pten-deficient mice. Biochem J. 2008;412:211–21.CrossRefPubMedGoogle Scholar
  18. 18.
    Algire C, Zakikhani M, Blouin MJ, Shuai JH, Pollak M. Metformin attenuates the stimulatory effect of a high-energy diet on in vivo llc1 carcinoma growth. Endocr Relat Cancer. 2008;15:833–9.CrossRefPubMedGoogle Scholar
  19. 19.
    Lai HC, Singh NP, Sasaki T. Development of artemisinin compounds for cancer treatment. Invest New Drugs. 2013;31:230–46.CrossRefPubMedGoogle Scholar
  20. 20.
    Zakikhani M, Dowling R, Fantus IG, Sonenberg N, Pollak M. Metformin is an amp kinase-dependent growth inhibitor for breast cancer cells. Cancer Res. 2006;66:10269–73.CrossRefPubMedGoogle Scholar
  21. 21.
    Ben Sahra I, Regazzetti C, Robert G, Laurent K, Le Marchand-Brustel Y, Auberger P, et al. Metformin, independent of AMPK, induces mTOR inhibition and cell-cycle arrest through REDD1. Cancer Res. 2011;71:4366–72.CrossRefPubMedGoogle Scholar
  22. 22.
    Tang JJ, Li JG, Qi W, Qiu WW, Li PS, Li BL, et al. Inhibition of srebp by a small molecule, betulin, improves hyperlipidemia and insulin resistance and reduces atherosclerotic plaques. Cell Metab. 2011;13:44–56.CrossRefPubMedGoogle Scholar
  23. 23.
    Wan Y, Jiang S, Lian LH, Bai T, Cui PH, Sun XT, et al. Betulinic acid and betulin ameliorate acute ethanol-induced fatty liver via tlr4 and stat3 in vivo and in vitro. Int Immunopharmacol. 2013;17:184–90.CrossRefPubMedGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2014

Authors and Affiliations

  1. 1.Department of PneumologyHuaihe Hospital of Henan UniversityKaifengChina

Personalised recommendations